PrecisionLife has appointed Bill Keating as chief commercial officer for diagnostics and healthcare, marking a significant step in the company’s expansion of its Mechanostic testing platform for complex chronic diseases. The Oxford-based precision medicine company announced the appointment on 8 January 2025, signalling an intensified focus on commercialising its non-invasive genotypic testing capabilities.

Clinical applications

The company’s proprietary disease insight platform has demonstrated capability across more than 50 complex chronic conditions, offering mechanism-based analysis and risk prediction at scale. The testing methodology identifies specific biological disease drivers and risk factors at the individual patient level, enabling personalised intervention strategies and treatment selection protocols.

Bill Keating

Healthcare implementation

Keating joins PrecisionLife with over two decades of experience in corporate and business development within the precision medicine sector, having held senior positions at Philips Healthcare, Zephyr AI, and Foundation Medicine. His appointment comes at a crucial phase in the company’s development of clinical applications that could impact the management of conditions affecting over 5 billion patients globally.

“I am thrilled to join PrecisionLife at such a transformative time,” said Keating. “I’m impressed by its unique ability to deliver mechanism-based insights and risk prediction in a massively scalable way across over 50 complex, chronic diseases. Our test platform and clinical decision support tool is making personalized treatment recommendations possible in multiple diseases for the first time.”

Clinical significance

The platform’s capacity for rapid differential triage of referrals and informed clinical pathway decisions represents a significant advancement in chronic disease management. The technology aims to address current inefficiencies in healthcare delivery, particularly regarding referral accuracy and prescription effectiveness.

PrecisionLife’s CEO, Steve Gardner, commented: “Our precision medicine solutions are enabling us to build pioneering clinical solutions with multiple international healthcare partners that provide rapid clinically actionable insights and enhance patient care and outcomes in diseases that have lacked adequate diagnostic tools for far too long.”

The company’s approach to precision medicine testing could transform current diagnostic paradigms, particularly in complex chronic conditions where traditional diagnostic methodologies have shown limitations. The platform’s ability to deliver mechanism-based insights at scale represents a significant advancement in personalised medicine implementation across healthcare systems.